We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avandia Sales in Steep Decline Even as Study Shows CV Risks Similar to Actos
Avandia Sales in Steep Decline Even as Study Shows CV Risks Similar to Actos
August 27, 2010
A new study showing GlaxoSmithKline’s (GSK) Avandia has cardiovascular (CV) risks similar to Takeda’s Actos may have come too late, as prescriptions for the embattled diabetes drug have plummeted as a result of the controversy.